Industry News
ERS Genomics and StemSight sign CRISPR/Cas9 license agreement
License agreement provides StemSight access to CRISPR/Cas9 technology to be applied in the development of cell therapies for corneal blindness
License agreement provides StemSight access to CRISPR/Cas9 technology to be applied in the development of cell therapies for corneal blindness
Nobel prize winning CRISPR technology to be applied in development of genetically engineered animal models
License agreement to enhance GenScript’s CRISPR offering for gene and cell therapy research
The license from ERS expands ZeClinics CRISPR IP portfolio and increases the validity and potency of zebrafish models for the drug discovery process